These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 37090728)

  • 1. Machine learning-based integration develops an immune-related risk model for predicting prognosis of high-grade serous ovarian cancer and providing therapeutic strategies.
    Wu Q; Tian R; He X; Liu J; Ou C; Li Y; Fu X
    Front Immunol; 2023; 14():1164408. PubMed ID: 37090728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Machine learning-based risk model incorporating tumor immune and stromal contexture predicts cancer prognosis and immunotherapy efficacy.
    He LN; Li H; Du W; Fu S; Luo L; Chen T; Zhang X; Chen C; Jiang Y; Wang Y; Wang Y; Yu H; Zhou Y; Lin Z; Zhao Y; Huang Y; Zhao H; Fang W; Yang Y; Zhang L; Hong S
    iScience; 2023 Jul; 26(7):107058. PubMed ID: 37416452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma.
    Wu J; Li L; Zhang H; Zhao Y; Zhang H; Wu S; Xu B
    Oncogene; 2021 Jul; 40(26):4413-4424. PubMed ID: 34108619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Comprehensive Analysis of Prognostic Indicators in Serous Ovarian Cancer Based on Leukocyte Migration and Immune Microenvironment.
    Pan J; Chen X; Yang L; Song Y; Liu J; Li L; Lin Y; Tang L; Qiu S; Xu Q
    Front Biosci (Landmark Ed); 2023 Jun; 28(6):130. PubMed ID: 37395023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor microenvironment-based signatures distinguish intratumoral heterogeneity, prognosis, and immunogenomic features of clear cell renal cell carcinoma.
    Anwaier A; Xu W; Liu W; Wei S; Tian X; Qu Y; Yang J; Zhang H; Ye D
    J Natl Cancer Cent; 2023 Sep; 3(3):236-249. PubMed ID: 39035192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tertiary Lymphoid Structures Are Associated with a Favorable Prognosis in High-Grade Serous Ovarian Cancer Patients.
    Zhang K; Xie X; Zou LH; Guo SQ
    Reprod Sci; 2023 Aug; 30(8):2468-2480. PubMed ID: 36759495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
    Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
    Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TMErisk score: A tumor microenvironment-based model for predicting prognosis and immunotherapy in patients with head and neck squamous cell carcinoma.
    Li Y; Pan X; Luo W; Gamalla Y; Ma Z; Zhou P; Dai C; Han D
    Heliyon; 2024 Jun; 10(11):e31877. PubMed ID: 38845978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multimodal radiomic machine learning approach to predict the LCK expression and clinical prognosis in high-grade serous ovarian cancer.
    Zhan F; He L; Yu Y; Chen Q; Guo Y; Wang L
    Sci Rep; 2023 Sep; 13(1):16397. PubMed ID: 37773310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
    Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
    Front Genet; 2022; 13():919389. PubMed ID: 35783281
    [No Abstract]   [Full Text] [Related]  

  • 11. Deciphering the immune landscape dominated by cancer-associated fibroblasts to investigate their potential in indicating prognosis and guiding therapeutic regimens in high grade serous ovarian carcinoma.
    Li Y; Tian R; Liu J; Li J; Tan H; Wu Q; Fu X
    Front Immunol; 2022; 13():940801. PubMed ID: 36119108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stromal infiltrating mast cells identify immunoevasive subtype high-grade serous ovarian cancer with poor prognosis and inferior immunotherapeutic response.
    Cao K; Zhang G; Zhang X; Yang M; Wang Y; He M; Lu J; Liu H
    Oncoimmunology; 2021; 10(1):1969075. PubMed ID: 34527431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and validation of pyroptosis-related gene landscape in prognosis and immunotherapy of ovarian cancer.
    Gao L; Ying F; Cai J; Peng M; Xiao M; Sun S; Zeng Y; Xiong Z; Cai L; Gao R; Wang Z
    J Ovarian Res; 2023 Jan; 16(1):27. PubMed ID: 36707884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune profiling reveals prognostic genes in high-grade serous ovarian cancer.
    Wu Y; Xia L; Zhao P; Deng Y; Guo Q; Zhu J; Chen X; Ju X; Wu X
    Aging (Albany NY); 2020 Jun; 12(12):11398-11415. PubMed ID: 32544083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Machine learning-derived identification of prognostic signature for improving prognosis and drug response in patients with ovarian cancer.
    Huan Q; Cheng S; Ma HF; Zhao M; Chen Y; Yuan X
    J Cell Mol Med; 2024 Jan; 28(1):e18021. PubMed ID: 37994489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular cluster mining of high-grade serous ovarian cancer via multi-omics data analysis aids precise medicine.
    Cai D; Liu T; Fang J; Liu Y
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):9151-9165. PubMed ID: 37178426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model constructions of chemosensitivity and prognosis of high grade serous ovarian cancer based on evaluation of immune microenvironment and immune response.
    Zhang H; Wu Y; Li H; Sun L; Meng X
    Cancer Cell Int; 2021 Nov; 21(1):593. PubMed ID: 34736480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A macrophage related signature for predicting prognosis and drug sensitivity in ovarian cancer based on integrative machine learning.
    Zhao B; Pei L
    BMC Med Genomics; 2023 Oct; 16(1):230. PubMed ID: 37784081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and Validation of an Immune-Related Gene-Pair Model of High-Grade Serous Ovarian Cancer After Platinum-Based Chemotherapy.
    Lin J; Xu X; Sun D; Li T
    Front Oncol; 2020; 10():626555. PubMed ID: 33680950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour microenvironment-based molecular profiling reveals ideal candidates for high-grade serous ovarian cancer immunotherapy.
    Lu X; Ji C; Jiang L; Zhu Y; Zhou Y; Meng J; Gao J; Lu T; Ye J; Yan F
    Cell Prolif; 2021 Mar; 54(3):e12979. PubMed ID: 33522069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.